Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Rheumatoid Arthritis

  Free Subscription


Articles published in Arthritis Res Ther

Retrieve available abstracts of 360 articles:
HTML format



Single Articles


    July 2021
  1. AJEGANOVA S, Andersson MLE, Frostegard J, Hafstrom I, et al
    Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.
    Arthritis Res Ther. 2021;23:201.
    PubMed     Abstract available


  2. IWAMOTO N, Sato S, Kurushima S, Michitsuji T, et al
    Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:197.
    PubMed     Abstract available


  3. MINAMINO H, Katsushima M, Fujita Y, Hashimoto M, et al
    Comment on "Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study": authors' reply.
    Arthritis Res Ther. 2021;23:195.
    PubMed    


  4. STOCKFELT M, Lundell AC, Hetland ML, Ostergaard M, et al
    Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
    Arthritis Res Ther. 2021;23:189.
    PubMed     Abstract available


  5. ANDONIAN BJ, Johannemann A, Hubal MJ, Pober DM, et al
    Altered skeletal muscle metabolic pathways, age, systemic inflammation, and low cardiorespiratory fitness associate with improvements in disease activity following high-intensity interval training in persons with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:187.
    PubMed     Abstract available


  6. MESSELINK MA, Roodenrijs NMT, van Es B, Hulsbergen-Veelken CAR, et al
    Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon.
    Arthritis Res Ther. 2021;23:184.
    PubMed     Abstract available


  7. JUNG SY, Koh JH, Kim KJ, Park YW, et al
    Switching from TNFalpha inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFalpha inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.
    Arthritis Res Ther. 2021;23:182.
    PubMed     Abstract available


  8. CORRADO A, Rotondo C, Mele A, Cici D, et al
    Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:180.
    PubMed     Abstract available


  9. KOO BS, Eun S, Shin K, Yoon H, et al
    Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics.
    Arthritis Res Ther. 2021;23:178.
    PubMed     Abstract available


  10. CHO SK, Kim H, Lee J, Nam E, et al
    Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.
    Arthritis Res Ther. 2021;23:176.
    PubMed     Abstract available


    June 2021
  11. MAARSEVEEN TD, Maurits MP, Niemantsverdriet E, van der Helm-van Mil AHM, et al
    Handwork vs machine: a comparison of rheumatoid arthritis patient populations as identified from EHR free-text by diagnosis extraction through machine-learning or traditional criteria-based chart review.
    Arthritis Res Ther. 2021;23:174.
    PubMed     Abstract available


  12. EBERHARD A, Bergman S, Mandl T, Olofsson T, et al
    Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study.
    Arthritis Res Ther. 2021;23:169.
    PubMed     Abstract available


  13. HUR B, Gupta VK, Huang H, Wright KA, et al
    Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity.
    Arthritis Res Ther. 2021;23:164.
    PubMed     Abstract available


  14. DEMORUELLE MK, Wang H, Davis RL, Visser A, et al
    Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:163.
    PubMed     Abstract available


  15. FERRAZ-AMARO I, Corrales A, Quevedo-Abeledo JC, Vegas-Revenga N, et al
    Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk.
    Arthritis Res Ther. 2021;23:162.
    PubMed     Abstract available


  16. GIOLLO A, Cioffi G, Ognibeni F, Orsolini G, et al
    Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:158.
    PubMed     Abstract available


  17. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
    Serum TNFalpha levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
    Arthritis Res Ther. 2021;23:154.
    PubMed     Abstract available


    May 2021
  18. RICHTER JG, Chehab G, Schwartz C, Ricken E, et al
    The PICASO cloud platform for improved holistic care in rheumatoid arthritis treatment-experiences of patients and clinicians.
    Arthritis Res Ther. 2021;23:151.
    PubMed     Abstract available


  19. MATSUMOTO H, Fujita Y, Matsuoka N, Temmoku J, et al
    Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD).
    Arthritis Res Ther. 2021;23:148.
    PubMed     Abstract available


  20. OLIVER J, Nair N, Orozco G, Smith S, et al
    Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.
    Arthritis Res Ther. 2021;23:139.
    PubMed    


    April 2021
  21. JIN S, Li M, Wang Q, Zeng X, et al
    Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT.
    Arthritis Res Ther. 2021;23:127.
    PubMed     Abstract available


  22. SEGU-VERGES C, Coma M, Kessel C, Smeets S, et al
    Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.
    Arthritis Res Ther. 2021;23:126.
    PubMed     Abstract available


  23. KIM KW, Kim BM, Won JY, Min HK, et al
    Regulation of osteoclastogenesis by mast cell in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:124.
    PubMed     Abstract available


  24. COMBE B, Allanore Y, Alten R, Caporali R, et al
    Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
    Arthritis Res Ther. 2021;23:119.
    PubMed     Abstract available


  25. JINNO S, Onishi A, Dubreuil M, Hashimoto M, et al
    Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
    Arthritis Res Ther. 2021;23:116.
    PubMed     Abstract available


  26. ZHU J, Niu Z, Alfredsson L, Klareskog L, et al
    Age at menarche, age at natural menopause, and risk of rheumatoid arthritis - a Mendelian randomization study.
    Arthritis Res Ther. 2021;23:108.
    PubMed     Abstract available


  27. MATSUMOTO Y, Shivappa N, Sugioka Y, Tada M, et al
    Change in dietary inflammatory index score is associated with control of long-term rheumatoid arthritis disease activity in a Japanese cohort: the TOMORROW study.
    Arthritis Res Ther. 2021;23:105.
    PubMed     Abstract available


  28. AKGUL A, Maddaloni M, Jun SM, Nelson AS, et al
    Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sjogren's syndrome.
    Arthritis Res Ther. 2021;23:99.
    PubMed     Abstract available


    March 2021
  29. WAN L, Gao Y, Gu J, Chi H, et al
    Total metabolic lesion volume of lymph nodes measured by (18)F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still's disease.
    Arthritis Res Ther. 2021;23:97.
    PubMed     Abstract available


  30. MINAMINO H, Katsushima M, Hashimoto M, Fujita Y, et al
    Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study.
    Arthritis Res Ther. 2021;23:96.
    PubMed     Abstract available


  31. RISTIC GG, Subota V, Stanisavljevic D, Vojvodic D, et al
    Impact of disease activity on impaired glucose metabolism in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:95.
    PubMed     Abstract available


  32. WEISEL K, Berger S, Thorn K, Taylor PC, et al
    A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:85.
    PubMed     Abstract available


  33. OIIVER J, Nair N, Orozco G, Smith S, et al
    Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.
    Arthritis Res Ther. 2021;23:80.
    PubMed     Abstract available


    February 2021
  34. TOYAMA S, Tokunaga D, Tsuchida S, Kushida R, et al
    Comprehensive assessment of alterations in hand deformities over 11 years in patients with rheumatoid arthritis using cluster analysis and analysis of covariance.
    Arthritis Res Ther. 2021;23:66.
    PubMed     Abstract available


  35. VODENCAREVIC A, Tascilar K, Hartmann F, Reiser M, et al
    Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs.
    Arthritis Res Ther. 2021;23:67.
    PubMed     Abstract available


  36. CONTRERAS-YANEZ I, Lavielle P, Clark P, Pascual-Ramos V, et al
    Markers of disease severity and positive family history are associated to significant risk perception in rheumatoid arthritis, while compliance with therapy is not: a cross-sectional study in 415 Mexican outpatients.
    Arthritis Res Ther. 2021;23:61.
    PubMed     Abstract available


  37. LIU M, Xie Z, Sun G, Chen L, et al
    Macrophage migration inhibitory factor may play a protective role in osteoarthritis.
    Arthritis Res Ther. 2021;23:59.
    PubMed     Abstract available


  38. NOWELL WB, Gavigan K, Kannowski CL, Cai Z, et al
    Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower.
    Arthritis Res Ther. 2021;23:53.
    PubMed     Abstract available


  39. KAY J, Jaworski J, Wojciechowski R, Wiland P, et al
    Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.
    Arthritis Res Ther. 2021;23:51.
    PubMed     Abstract available


  40. TERSLEV L, Brahe CH, Ostergaard M, Fana V, et al
    Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission.
    Arthritis Res Ther. 2021;23:48.
    PubMed     Abstract available


    January 2021
  41. TAN LK, Too CL, Diaz-Gallo LM, Wahinuddin S, et al
    The spectrum of association in HLA region with rheumatoid arthritis in a diverse Asian population: evidence from the MyEIRA case-control study.
    Arthritis Res Ther. 2021;23:46.
    PubMed     Abstract available


  42. HEMSHEKHAR M, Anaparti V, El-Gabalawy H, Mookherjee N, et al
    A bioavailable form of curcumin, in combination with vitamin-D- and omega-3-enriched diet, modifies disease onset and outcomes in a murine model of collagen-induced arthritis.
    Arthritis Res Ther. 2021;23:39.
    PubMed     Abstract available


  43. WU C, Tan S, Liu L, Cheng S, et al
    Transcriptome-wide association study identifies susceptibility genes for rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:38.
    PubMed     Abstract available


  44. FROSTEGARD J, Ahmed S, Hafstrom I, Ajeganova S, et al
    Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-alpha: potential underlying mechanisms.
    Arthritis Res Ther. 2021;23:32.
    PubMed     Abstract available


  45. MUN S, Lee J, Park M, Shin J, et al
    Serum biomarker panel for the diagnosis of rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:31.
    PubMed     Abstract available


  46. WRIGHT M, Smed MK, Nelson JL, Olsen J, et al
    Is gene expression among women with rheumatoid arthritis dysregulated during a postpartum flare?
    Arthritis Res Ther. 2021;23:30.
    PubMed     Abstract available


  47. RYDELL E, Forslind K, Nilsson JA, Karlsson M, et al
    Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study.
    Arthritis Res Ther. 2021;23:27.
    PubMed     Abstract available


  48. SOLOMON DH, Xu C, Collins J, Kim SC, et al
    The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy.
    Arthritis Res Ther. 2021;23:26.
    PubMed     Abstract available


  49. MURRAY K, Turk M, Alammari Y, Young F, et al
    Long-term remission and biologic persistence rates: 12-year real-world data.
    Arthritis Res Ther. 2021;23:25.
    PubMed     Abstract available


  50. SIMON TA, Dong L, Winthrop KL
    Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data.
    Arthritis Res Ther. 2021;23:17.
    PubMed     Abstract available


  51. DAVIGNON JL, Combe B, Cantagrel A
    Cytomegalovirus infection: friend or foe in rheumatoid arthritis?
    Arthritis Res Ther. 2021;23:16.
    PubMed     Abstract available


  52. DROBINSKI PJ, Bay-Jensen AC, Karsdal MA, Sardar S, et al
    Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
    Arthritis Res Ther. 2021;23:13.
    PubMed     Abstract available


  53. KAMEDA H, Takeuchi T, Yamaoka K, Oribe M, et al
    Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Arthritis Res Ther. 2021;23:9.
    PubMed     Abstract available


  54. EMERY P, Durez P, Hueber AJ, de la Torre I, et al
    Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
    Arthritis Res Ther. 2021;23:3.
    PubMed     Abstract available


  55. ROHRICH DC, van de Wetering EHM, Rennings AJ, Arts EE, et al
    Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study.
    Arthritis Res Ther. 2021;23:2.
    PubMed     Abstract available


  56. CURTIS JR, Weinblatt ME, Shadick NA, Brahe CH, et al
    Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.
    Arthritis Res Ther. 2021;23:1.
    PubMed     Abstract available


    December 2020
  57. BYWALL KS, Kihlbom U, Hansson M, Falahee M, et al
    Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients.
    Arthritis Res Ther. 2020;22:288.
    PubMed     Abstract available


  58. CHOI C, Jeong W, Ghang B, Park Y, et al
    Correction to: Cyr61 synthesis is induced by interleukin-6 and promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:287.
    PubMed    


  59. NOVELLA-NAVARRO M, Plasencia C, Tornero C, Navarro-Compan V, et al
    Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:284.
    PubMed     Abstract available


  60. CURTIS JR, Xie F, Crowson CS, Sasso EH, et al
    Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients.
    Arthritis Res Ther. 2020;22:282.
    PubMed     Abstract available


    November 2020
  61. NOSRATI Z, Bergamo M, Rodriguez-Rodriguez C, Saatchi K, et al
    Refinement and validation of infrared thermal imaging (IRT): a non-invasive technique to measure disease activity in a mouse model of rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:281.
    PubMed     Abstract available


  62. VERSTAPPEN M, Niemantsverdriet E, Matthijssen XME, le Cessie S, et al
    Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:276.
    PubMed     Abstract available


  63. CHOI C, Jeong W, Ghang B, Park Y, et al
    Cyr61 synthesis is induced by interleukin-6 and promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:275.
    PubMed     Abstract available


  64. DAKKAK YJ, Niemantsverdriet E, van der Helm-van Mil AHM, Reijnierse M, et al
    Increased frequency of intermetatarsal and submetatarsal bursitis in early rheumatoid arthritis: a large case-controlled MRI study.
    Arthritis Res Ther. 2020;22:277.
    PubMed     Abstract available


  65. ROOS LJUNGBERG K, Borjesson E, Martinsson K, Wettero J, et al
    Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:274.
    PubMed     Abstract available


  66. MURATA K, Ito H, Hashimoto M, Murakami K, et al
    Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort.
    Arthritis Res Ther. 2020;22:268.
    PubMed     Abstract available


    October 2020
  67. SAUER BC, Chen W, Xu Y, Shen J, et al
    Empirical evidence of disease activity thresholds used to indicate need for major therapeutic change in US veterans with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:253.
    PubMed     Abstract available


  68. HOU SM, Chen PC, Lin CM, Fang ML, et al
    CXCL1 contributes to IL-6 expression in osteoarthritis and rheumatoid arthritis synovial fibroblasts by CXCR2, c-Raf, MAPK, and AP-1 pathway.
    Arthritis Res Ther. 2020;22:251.
    PubMed     Abstract available


  69. TAKEUCHI T, Tanaka Y, Erdman J, Kaneko Y, et al
    ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.
    Arthritis Res Ther. 2020;22:252.
    PubMed     Abstract available


  70. STRAND V, Boklage SH, Kimura T, Joly F, et al
    High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Arthritis Res Ther. 2020;22:250.
    PubMed     Abstract available


  71. ALDRIDGE J, Ekwall AH, Mark L, Bergstrom B, et al
    T helper cells in synovial fluid of patients with rheumatoid arthritis primarily have a Th1 and a CXCR3(+)Th2 phenotype.
    Arthritis Res Ther. 2020;22:245.
    PubMed     Abstract available


  72. CURTIS JR, Xie F, Zhou H, Salchert D, et al
    Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available.
    Arthritis Res Ther. 2020;22:242.
    PubMed     Abstract available


  73. STRAND V, Kaine J, Alten R, Wallenstein G, et al
    Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Arthritis Res Ther. 2020;22:243.
    PubMed     Abstract available


  74. THUDIUM CS, Bay-Jensen AC, Cahya S, Dow ER, et al
    The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:235.
    PubMed     Abstract available


  75. PFEIL A, Nussbaum A, Renz DM, Hoffmann T, et al
    Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial.
    Arthritis Res Ther. 2020;22:229.
    PubMed     Abstract available


  76. WANG Y, Zhang K, Yuan X, Xu N, et al
    miR-431-5p regulates cell proliferation and apoptosis in fibroblast-like synoviocytes in rheumatoid arthritis by targeting XIAP.
    Arthritis Res Ther. 2020;22:231.
    PubMed     Abstract available


    September 2020
  77. GENITSARIDI I, Flouri I, Plexousakis D, Marias K, et al
    Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.
    Arthritis Res Ther. 2020;22:226.
    PubMed     Abstract available


  78. SALAFFI F, Di Carlo M, Carotti M, Ceccarelli L, et al
    Predictive validity of the 5-item Compliance Questionnaire for Rheumatology (CQR5) in detecting poor adherence of patients with rheumatoid arthritis to biological medication.
    Arthritis Res Ther. 2020;22:227.
    PubMed     Abstract available


  79. TOUSSIROT E, Marotte H, Mulleman D, Cormier G, et al
    Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study.
    Arthritis Res Ther. 2020;22:224.
    PubMed     Abstract available


  80. MIN HK, Won JY, Kim BM, Lee KA, et al
    Interleukin (IL)-25 suppresses IL-22-induced osteoclastogenesis in rheumatoid arthritis via STAT3 and p38 MAPK/IkappaBalpha pathway.
    Arthritis Res Ther. 2020;22:222.
    PubMed     Abstract available


  81. XUE J, Xu L, Zhu H, Bai M, et al
    CD14(+)CD16(-) monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK.
    Arthritis Res Ther. 2020;22:221.
    PubMed     Abstract available


  82. VAN BOHEEMEN L, Bolt JW, Ter Wee MM, de Jong HM, et al
    Patients' and rheumatologists' perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis.
    Arthritis Res Ther. 2020;22:217.
    PubMed     Abstract available


    August 2020
  83. XU J, Jiang C, Cai Y, Guo Y, et al
    Intervening upregulated SLC7A5 could mitigate inflammatory mediator by mTOR-P70S6K signal in rheumatoid arthritis synoviocytes.
    Arthritis Res Ther. 2020;22:200.
    PubMed     Abstract available


  84. JULIA A, Avila G, Celis R, Sanmarti R, et al
    Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:196.
    PubMed     Abstract available


  85. SMOLEN JS, Kang YM, Yoo WH, Emery P, et al
    Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:188.
    PubMed     Abstract available


  86. YANG X, Guo Q, Feng T, Lu Q, et al
    IL13Ralpha1 protects against rheumatoid arthritis by combating the apoptotic resistance of fibroblast-like synoviocytes.
    Arthritis Res Ther. 2020;22:184.
    PubMed     Abstract available


    July 2020
  87. TACHIBANA M, Yonemoto Y, Okamura K, Suto T, et al
    Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?
    Arthritis Res Ther. 2020;22:178.
    PubMed     Abstract available


  88. PARK JK, Jang YJ, Oh BR, Shin J, et al
    Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:176.
    PubMed     Abstract available


  89. REED E, Hedstrom AK, Hansson M, Mathsson-Alm L, et al
    Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
    Arthritis Res Ther. 2020;22:170.
    PubMed     Abstract available


  90. EMERY P, Tanaka Y, Cardillo T, Schlichting D, et al
    Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:166.
    PubMed     Abstract available


    June 2020
  91. OTA T, Ota SI, Uchino A, Nagano S, et al
    IgG anti-hinge antibodies against IgG4 F(ab')2 fragments generated using pepsin are useful diagnostic markers for rheumatoid arthritis: implications of the possible roles of metalloproteinases and IgG subclasses in generating immunogenic hinge epitope
    Arthritis Res Ther. 2020;22:161.
    PubMed     Abstract available


  92. MA MHY, Defranoux N, Li W, Sasso EH, et al
    A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:158.
    PubMed     Abstract available


  93. TAKEUCHI T, Tanaka Y, Tanaka S, Kawakami A, et al
    Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
    Arthritis Res Ther. 2020;22:155.
    PubMed     Abstract available


  94. JIANG X, Alfredsson L
    Modifiable environmental exposure and risk of rheumatoid arthritis-current evidence from genetic studies.
    Arthritis Res Ther. 2020;22:154.
    PubMed     Abstract available


  95. HA YJ, Lee SM, Mun CH, Kim HJ, et al
    Methotrexate-loaded multifunctional nanoparticles with near-infrared irradiation for the treatment of rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:146.
    PubMed     Abstract available


  96. EBINA K, Hirano T, Maeda Y, Yamamoto W, et al
    Drug retention of 7 biologics and tofacitinib in biologics-naive and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
    Arthritis Res Ther. 2020;22:142.
    PubMed     Abstract available


  97. GENOVESE MC, Fleischmann R, Kivitz A, Lee EB, et al
    Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
    Arthritis Res Ther. 2020;22:139.
    PubMed     Abstract available


  98. STRAND V, Pope J, Tundia N, Friedman A, et al
    Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Arthritis Res Ther. 2020;22:137.
    PubMed     Abstract available


  99. KAWABE A, Nakano K, Kubo S, Asakawa T, et al
    Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
    Arthritis Res Ther. 2020;22:136.
    PubMed     Abstract available


    May 2020
  100. EMERY P, Tanaka Y, Cardillo T, Schlichting D, et al
    Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:115.
    PubMed     Abstract available


  101. LEE HR, Yoo SJ, Kim J, Yoo IS, et al
    The effect of nicotinamide adenine dinucleotide phosphate oxidase 4 on migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:116.
    PubMed     Abstract available


  102. SONG YJ, Choi IA, Meylan F, Demoruelle MK, et al
    Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF.
    Arthritis Res Ther. 2020;22:106.
    PubMed     Abstract available


  103. JARLBORG M, Courvoisier DS, Lamacchia C, Martinez Prat L, et al
    Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.
    Arthritis Res Ther. 2020;22:105.
    PubMed     Abstract available


  104. ZHANG H, Zhang H, Gao D, Xie W, et al
    Overlapping Sjogren's syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019.
    Arthritis Res Ther. 2020;22:100.
    PubMed     Abstract available


    April 2020
  105. VINSON D, Molet-Benhamou L, Degboe Y, den Broeder A, et al
    Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis.
    Arthritis Res Ther. 2020;22:97.
    PubMed     Abstract available


  106. DIERCKX S, Sokolova T, Lauwerys BR, Avramovska A, et al
    Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
    Arthritis Res Ther. 2020;22:96.
    PubMed     Abstract available


  107. TUNCEL J, Holmberg J, Haag S, Hopkins MH, et al
    Self-reactive T cells induce and perpetuate chronic relapsing arthritis.
    Arthritis Res Ther. 2020;22:95.
    PubMed     Abstract available


  108. WIBETOE G, Sexton J, Ikdahl E, Rollefstad S, et al
    Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models.
    Arthritis Res Ther. 2020;22:90.
    PubMed     Abstract available


  109. YATES M, Bechman K, Dennison EM, MacGregor AJ, et al
    Data quality predicts care quality: findings from a national clinical audit.
    Arthritis Res Ther. 2020;22:87.
    PubMed     Abstract available


  110. FUJITA Y, Asano T, Matsuoka N, Temmoku J, et al
    Differential regulation and correlation between galectin-9 and anti-CCP antibody (ACPA) in rheumatoid arthritis patients.
    Arthritis Res Ther. 2020;22:80.
    PubMed     Abstract available


  111. KIM EK, Min HK, Lee SY, Kim DS, et al
    Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome.
    Arthritis Res Ther. 2020;22:77.
    PubMed     Abstract available


  112. GABAY C, Burmester GR, Strand V, Msihid J, et al
    Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Arthritis Res Ther. 2020;22:70.
    PubMed     Abstract available


  113. DAKKAK YJ, Boer AC, Boeters DM, Niemantsverdriet E, et al
    The relation between physical joint examination and MRI-depicted inflammation of metatarsophalangeal joints in early arthritis.
    Arthritis Res Ther. 2020;22:67.
    PubMed     Abstract available


    March 2020
  114. LIU PC, Ssu CT, Tsao YP, Liou TL, et al
    Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.
    Arthritis Res Ther. 2020;22:64.
    PubMed     Abstract available


  115. SUN W, Ma J, Zhao H, Xiao C, et al
    Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA-146a-5p in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:61.
    PubMed     Abstract available


  116. GENOVESE MC, Sanchez-Burson J, Oh M, Balazs E, et al
    Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:60.
    PubMed     Abstract available


  117. BOETERS DM, van der Helm-van Mil AHM
    Response to: "Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation" by Masi and Fleischmann.
    Arthritis Res Ther. 2020;22:55.
    PubMed    


  118. YOKOYAMA-KOKURYO W, Yamazaki H, Takeuchi T, Amano K, et al
    Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:46.
    PubMed     Abstract available


  119. TAKEUCHI T, Tanaka Y, Tanaka S, Kawakami A, et al
    Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
    Arthritis Res Ther. 2020;22:47.
    PubMed     Abstract available


  120. QIAN Y, Zhang L, Wu DJH, Xie Z, et al
    Genetic predisposition to smoking is associated with risk of rheumatoid arthritis: a Mendelian randomization study.
    Arthritis Res Ther. 2020;22:44.
    PubMed     Abstract available


  121. OCHI S, Saito K, Mizoguchi F, Kato S, et al
    Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study.
    Arthritis Res Ther. 2020;22:41.
    PubMed     Abstract available


  122. ABRAR DB, Schleich C, Nebelung S, Frenken M, et al
    High-resolution MRI of flexor tendon pulleys using a 16-channel hand coil: disease detection and differentiation of psoriatic and rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:40.
    PubMed     Abstract available


    February 2020
  123. DURET PM, Meyer N, Saraux A, Devauchelle-Pensec V, et al
    Seasonal effect on fatigue, pain and dryness in primary Sjogren's syndrome.
    Arthritis Res Ther. 2020;22:39.
    PubMed     Abstract available


  124. LACOMBE V, Lacout C, Lozac'h P, Ghali A, et al
    Unstimulated whole saliva flow for diagnosis of primary Sjogren's syndrome: time to revisit the threshold?
    Arthritis Res Ther. 2020;22:38.
    PubMed     Abstract available


  125. GONZALEZ-FEBLES J, Rodriguez-Lozano B, Sanchez-Piedra C, Garnier-Rodriguez J, et al
    Association between periodontitis and anti-citrullinated protein antibodies in rheumatoid arthritis patients: a cross-sectional study.
    Arthritis Res Ther. 2020;22:27.
    PubMed     Abstract available


  126. TRIMOVA G, Yamagata K, Iwata S, Hirata S, et al
    Tumour necrosis factor alpha promotes secretion of 14-3-3eta by inducing necroptosis in macrophages.
    Arthritis Res Ther. 2020;22:24.
    PubMed     Abstract available


  127. KUETTEL D, Glinatsi D, Ostergaard M, Terslev L, et al
    Serial magnetic resonance imaging and ultrasound examinations demonstrate differential inflammatory lesion patterns in soft tissue and bone upon patient-reported flares in rheumatoid arthritis.
    Arthritis Res Ther. 2020;22:19.
    PubMed     Abstract available


    January 2020
  128. MASI AT, Fleischmann R
    Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et al.
    Arthritis Res Ther. 2020;22:17.
    PubMed    


  129. SAMARPITA S, Kim JY, Rasool MK, Kim KS, et al
    Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug.
    Arthritis Res Ther. 2020;22:16.
    PubMed     Abstract available


  130. CAGNOTTO G, Willim M, Nilsson JA, Compagno M, et al
    Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register.
    Arthritis Res Ther. 2020;22:15.
    PubMed     Abstract available


  131. RAUWEL B, Degboe Y, Nigon D, Boyer JF, et al
    Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients.
    Arthritis Res Ther. 2020;22:13.
    PubMed     Abstract available


  132. TEN BRINCK RM, Boeters DM, van Steenbergen HW, van der Helm-van Mil AHM, et al
    Improvement of symptoms in clinically suspect arthralgia and resolution of subclinical joint inflammation: a longitudinal study in patients that did not progress to clinical arthritis.
    Arthritis Res Ther. 2020;22:11.
    PubMed     Abstract available


  133. GAVIGAN K, Nowell WB, Serna MS, Stark JL, et al
    Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.
    Arthritis Res Ther. 2020;22:4.
    PubMed     Abstract available


    December 2019
  134. KATSUMATA K, Ishihara J, Fukunaga K, Ishihara A, et al
    Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF-alpha antibody in a murine model of rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:298.
    PubMed     Abstract available


  135. FROMM S, Cunningham CC, Dunne MR, Veale DJ, et al
    Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:297.
    PubMed     Abstract available


  136. BRINK M, Lundquist A, Alexeyenko A, Lejon K, et al
    Protein profiling and network enrichment analysis in individuals before and after the onset of rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:288.
    PubMed     Abstract available


  137. CURTIS JR, Xie F, Kay J, Kallich JD, et al
    Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:285.
    PubMed     Abstract available


  138. LEE KA, Kim KW, Kim BM, Won JY, et al
    Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:283.
    PubMed     Abstract available


  139. MO YQ, Yang ZH, Wang JW, Li QH, et al
    The value of MRI examination on bilateral hands including proximal interphalangeal joints for disease assessment in patients with early rheumatoid arthritis: a cross-sectional cohort study.
    Arthritis Res Ther. 2019;21:279.
    PubMed     Abstract available


  140. STRAND V, Pope J, Tundia N, Friedman A, et al
    Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Arthritis Res Ther. 2019;21:272.
    PubMed     Abstract available


  141. DE MOEL EC, Rech J, Mahler M, Roth J, et al
    Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
    Arthritis Res Ther. 2019;21:268.
    PubMed     Abstract available


  142. STRAND V, Schiff M, Tundia N, Friedman A, et al
    Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Arthritis Res Ther. 2019;21:263.
    PubMed     Abstract available


    November 2019
  143. TEN KLOOSTER PM, de Graaf N, Vonkeman HE
    Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-interventional, longitudinal cohort study.
    Arthritis Res Ther. 2019;21:257.
    PubMed     Abstract available


  144. FUKUDA W, Hanyu T, Katayama M, Mizuki S, et al
    Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
    Arthritis Res Ther. 2019;21:255.
    PubMed     Abstract available


  145. ZACCARDELLI A, Liu X, Ford JA, Cui J, et al
    Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:246.
    PubMed     Abstract available


  146. LUKAS C, Mary J, Debandt M, Daien C, et al
    Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Arthritis Res Ther. 2019;21:243.
    PubMed     Abstract available


  147. BERTHELOT JM, Le Goff B, Maugars Y
    Bone marrow mesenchymal stem cells in rheumatoid arthritis, spondyloarthritis, and ankylosing spondylitis: problems rather than solutions?
    Arthritis Res Ther. 2019;21:239.
    PubMed     Abstract available


  148. TEN KLOOSTER PM, Versteeg LGA, Oude Voshaar MAH, de la Torre I, et al
    Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    Arthritis Res Ther. 2019;21:237.
    PubMed     Abstract available


  149. SMOLEN J, Fleischmann R, Aletaha D, Li Y, et al
    Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials.
    Arthritis Res Ther. 2019;21:231.
    PubMed     Abstract available


  150. SIMON TA, Boers M, Hochberg M, Baker N, et al
    Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Arthritis Res Ther. 2019;21:228.
    PubMed     Abstract available


  151. VAN DER HELM-VAN MIL AHM
    How thorough clinical observational studies on rheumatoid arthritis can have an impact on the field.
    Arthritis Res Ther. 2019;21:227.
    PubMed    


  152. RAZA K
    Early rheumatoid arthritis is characterised by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin.
    Arthritis Res Ther. 2019;21:226.
    PubMed     Abstract available


    October 2019
  153. WANG H, Li S, Zhang G, Wu H, et al
    Potential therapeutic effects of cyanidin-3-O-glucoside on rheumatoid arthritis by relieving inhibition of CD38+ NK cells on Treg cell differentiation.
    Arthritis Res Ther. 2019;21:220.
    PubMed     Abstract available


  154. FARUTIN V, Prod'homme T, McConnell K, Washburn N, et al
    Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.
    Arthritis Res Ther. 2019;21:216.
    PubMed     Abstract available


  155. CONAGHAN PG, Ostergaard M, Troum O, Bowes MA, et al
    Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:214.
    PubMed     Abstract available


    September 2019
  156. GLIMM AM, Sprenger LI, Haugen IK, Mansmann U, et al
    Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period.
    Arthritis Res Ther. 2019;21:209.
    PubMed     Abstract available


  157. RUSCITTI P, Cipriani P, Liakouli V, Iacono D, et al
    Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.
    Arthritis Res Ther. 2019;21:204.
    PubMed     Abstract available


    August 2019
  158. TAKAKI-KUWAHARA A, Arinobu Y, Miyawaki K, Yamada H, et al
    CCR6+ group 3 innate lymphoid cells accumulate in inflamed joints in rheumatoid arthritis and produce Th17 cytokines.
    Arthritis Res Ther. 2019;21:198.
    PubMed     Abstract available


  159. JOO YB, Lim YH, Kim KJ, Park KS, et al
    Respiratory viral infections and the risk of rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:199.
    PubMed     Abstract available


  160. CALLHOFF J, Dietrich T, Chubrieva M, Klotsche J, et al
    A patient-reported questionnaire developed in a German early arthritis cohort to assess periodontitis in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:197.
    PubMed     Abstract available


  161. GU KN, Bang SY, Lee HS, Park Y, et al
    Deletion at 2q14.3 is associated with worse response to TNF-alpha blockers in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:195.
    PubMed     Abstract available


  162. TESSER J, Kafka S, DeHoratius RJ, Xu S, et al
    Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those >/= 65 years of age.
    Arthritis Res Ther. 2019;21:190.
    PubMed     Abstract available


    July 2019
  163. TOMIZAWA T, Ito H, Murata K, Hashimoto M, et al
    Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:174.
    PubMed     Abstract available


  164. EUSTACE AD, McNaughton EF, King S, Kehoe O, et al
    Soluble syndecan-3 binds chemokines, reduces leukocyte migration in vitro and ameliorates disease severity in models of rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:172.
    PubMed     Abstract available


  165. PENG A, Lu X, Huang J, He M, et al
    Rheumatoid arthritis synovial fibroblasts promote TREM-1 expression in monocytes via COX-2/PGE2 pathway.
    Arthritis Res Ther. 2019;21:169.
    PubMed     Abstract available


  166. TANAKA Y, Smolen JS, Jones H, Szumski A, et al
    The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:164.
    PubMed     Abstract available


  167. TERSLEV L, Christensen R, Aga AB, Sexton J, et al
    Assessing synovitis in the hands in patients with rheumatoid arthritis by ultrasound: an agreement study exploring the most inflammatory active side from two Norwegian trials.
    Arthritis Res Ther. 2019;21:166.
    PubMed     Abstract available


    June 2019
  168. ELLEGAARD K, von Bulow C, Ropke A, Bartholdy C, et al
    Hand exercise for women with rheumatoid arthritis and decreased hand function: an exploratory randomized controlled trial.
    Arthritis Res Ther. 2019;21:158.
    PubMed     Abstract available


  169. MA JD, Jing J, Wang JW, Yan T, et al
    A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients.
    Arthritis Res Ther. 2019;21:153.
    PubMed     Abstract available


  170. OZEN G, Pedro S, Schumacher R, Simon TA, et al
    Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Arthritis Res Ther. 2019;21:141.
    PubMed     Abstract available


  171. HU Y, Wang B, Shen J, Low SA, et al
    Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:143.
    PubMed     Abstract available


  172. MOUTERDE G, Rincheval N, Lukas C, Daien C, et al
    Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
    Arthritis Res Ther. 2019;21:140.
    PubMed     Abstract available


  173. CHOQUETTE D, Bessette L, Alemao E, Haraoui B, et al
    Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata(R) clinical database and registry.
    Arthritis Res Ther. 2019;21:138.
    PubMed     Abstract available


  174. CAI Y, Jiang C, Zhu J, Xu K, et al
    miR-449a inhibits cell proliferation, migration, and inflammation by regulating high-mobility group box protein 1 and forms a mutual inhibition loop with Yin Yang 1 in rheumatoid arthritis fibroblast-like synoviocytes.
    Arthritis Res Ther. 2019;21:134.
    PubMed     Abstract available


    May 2019
  175. JAWORSKI J, Matucci-Cerinic M, Schulze-Koops H, Buch MH, et al
    Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-
    Arthritis Res Ther. 2019;21:130.
    PubMed     Abstract available


  176. MUSTONEN AM, Kakela R, Lehenkari P, Huhtakangas J, et al
    Distinct fatty acid signatures in infrapatellar fat pad and synovial fluid of patients with osteoarthritis versus rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:124.
    PubMed     Abstract available


  177. FAN Y, Yang X, Zhao J, Sun X, et al
    Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:123.
    PubMed     Abstract available


  178. PARK MC, Matsuno H, Kim J, Park SH, et al
    Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, d
    Arthritis Res Ther. 2019;21:122.
    PubMed     Abstract available


  179. ALIVERNINI S, Bruno D, Tolusso B, Bui L, et al
    Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:116.
    PubMed     Abstract available


  180. LAMAS JR, Fernandez-Gutierrez B, Mucientes A, Marco F, et al
    RNA sequencing of mesenchymal stem cells reveals a blocking of differentiation and immunomodulatory activities under inflammatory conditions in rheumatoid arthritis patients.
    Arthritis Res Ther. 2019;21:112.
    PubMed     Abstract available


  181. EBINA K, Hashimoto M, Yamamoto W, Hirano T, et al
    Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Arthritis Res Ther. 2019;21:114.
    PubMed     Abstract available


    April 2019
  182. WINTHROP KL, Bingham CO 3rd, Komocsar WJ, Bradley J, et al
    Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
    Arthritis Res Ther. 2019;21:102.
    PubMed     Abstract available


  183. TAYLOR PC, Saurigny D, Vencovsky J, Takeuchi T, et al
    Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or
    Arthritis Res Ther. 2019;21:101.
    PubMed     Abstract available


  184. SUN X, Deng X, Xie W, Wang L, et al
    The agreement between ultrasound-determined joint inflammation and clinical signs in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:100.
    PubMed     Abstract available


  185. TANAKA Y, Wada K, Takahashi Y, Hagino O, et al
    Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Arthritis Res Ther. 2019;21:99.
    PubMed     Abstract available


  186. POLISKA S, Besenyei T, Vegh E, Hamar A, et al
    Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:94.
    PubMed     Abstract available


  187. EBINA K, Hashimoto M, Yamamoto W, Hirano T, et al
    Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Arthritis Res Ther. 2019;21:91.
    PubMed     Abstract available


  188. WOLLENHAUPT J, Lee EB, Curtis JR, Silverfield J, et al
    Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
    Arthritis Res Ther. 2019;21:89.
    PubMed     Abstract available


  189. SONG G, Lu Q, Fan H, Zhang X, et al
    Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:87.
    PubMed     Abstract available


    March 2019
  190. COHEN S, Pablos JL, Pavelka K, Muller GA, et al
    An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:84.
    PubMed     Abstract available


  191. YU S, Lu Y, Zong M, Tan Q, et al
    Hypoxia-induced miR-191-C/EBPbeta signaling regulates cell proliferation and apoptosis of fibroblast-like synoviocytes from patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:78.
    PubMed     Abstract available


  192. TANAKA Y, Wada K, Takahashi Y, Hagino O, et al
    Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Arthritis Res Ther. 2019;21:79.
    PubMed     Abstract available


  193. FERREIRA CC, Campi-Azevedo AC, Peruhype-Magalhaes V, Coelho-Dos-Reis JG, et al
    Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:75.
    PubMed     Abstract available


    February 2019
  194. MADISON A, Andersen BL, Ajam A
    Response to: "A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial".
    Arthritis Res Ther. 2019;21:65.
    PubMed    


  195. DAKKAK YJ, Boeters DM, Boer AC, Reijnierse M, et al
    What is the additional value of MRI of the foot to the hand in undifferentiated arthritis to predict rheumatoid arthritis development?
    Arthritis Res Ther. 2019;21:56.
    PubMed     Abstract available


  196. POOLMAN TM, Gibbs J, Walker AL, Dickson S, et al
    Rheumatoid arthritis reprograms circadian output pathways.
    Arthritis Res Ther. 2019;21:47.
    PubMed     Abstract available


  197. HAFSTROM I, Ajeganova S, Forslind K, Svensson B, et al
    Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort.
    Arthritis Res Ther. 2019;21:45.
    PubMed     Abstract available


    January 2019
  198. VOMERO M, Manganelli V, Barbati C, Colasanti T, et al
    Reduction of autophagy and increase in apoptosis correlates with a favorable clinical outcome in patients with rheumatoid arthritis treated with anti-TNF drugs.
    Arthritis Res Ther. 2019;21:39.
    PubMed     Abstract available


  199. ATEHORTUA L, Rojas M, Vasquez G, Munoz-Vahos CH, et al
    Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:34.
    PubMed     Abstract available


  200. GHOSH-SWABY OR, Kuriya B
    Awareness and perceived risk of cardiovascular disease among individuals living with rheumatoid arthritis is low: results of a systematic literature review.
    Arthritis Res Ther. 2019;21:33.
    PubMed     Abstract available


  201. DE MOEL EC, Derksen VFAM, Trouw LA, Bang H, et al
    In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.
    Arthritis Res Ther. 2019;21:28.
    PubMed     Abstract available


  202. RODRIGUEZ-LOZANO B, Gonzalez-Febles J, Garnier-Rodriguez JL, Dadlani S, et al
    Association between severity of periodontitis and clinical activity in rheumatoid arthritis patients: a case-control study.
    Arthritis Res Ther. 2019;21:27.
    PubMed     Abstract available


  203. FRENKEN M, Schleich C, Brinks R, Abrar DB, et al
    The value of the simplified RAMRIS-5 in early RA patients under methotrexate therapy using high-field MRI.
    Arthritis Res Ther. 2019;21:21.
    PubMed     Abstract available


  204. KONDO Y, Suzuki K, Inoue Y, Sakata K, et al
    Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:14.
    PubMed     Abstract available


  205. SZEKANECZ Z, Raterman HG, Petho Z, Lems WF, et al
    Common mechanisms and holistic care in atherosclerosis and osteoporosis.
    Arthritis Res Ther. 2019;21:15.
    PubMed     Abstract available


  206. TANNER MR, Pennington MW, Chauhan SS, Laragione T, et al
    KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:6.
    PubMed     Abstract available


  207. HU Q, Shi H, Zeng T, Liu H, et al
    Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease.
    Arthritis Res Ther. 2019;21:9.
    PubMed     Abstract available


  208. KOPPEJAN H, Jansen DTSL, Hameetman M, Thomas R, et al
    Altered composition and phenotype of mucosal-associated invariant T cells in early untreated rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:3.
    PubMed     Abstract available


    December 2018
  209. ANDONIAN BJ, Bartlett DB, Huebner JL, Willis L, et al
    Effect of high-intensity interval training on muscle remodeling in rheumatoid arthritis compared to prediabetes.
    Arthritis Res Ther. 2018;20:283.
    PubMed     Abstract available


  210. INCIARTE-MUNDO J, Ramirez J, Hernandez MV, Ruiz-Esquide V, et al
    Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Arthritis Res Ther. 2018;20:275.
    PubMed     Abstract available


  211. BARBATI C, Vomero M, Colasanti T, Diociaiuti M, et al
    TNFalpha expressed on the surface of microparticles modulates endothelial cell fate in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:273.
    PubMed     Abstract available


  212. CHEN YM, Chang CY, Chen HH, Hsieh CW, et al
    Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy.
    Arthritis Res Ther. 2018;20:268.
    PubMed     Abstract available


  213. PANOPOULOS S, Tektonidou M, Drosos AA, Liossis SN, et al
    Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study.
    Arthritis Res Ther. 2018;20:267.
    PubMed     Abstract available


  214. BISSELL LA, Erhayiem B, Fent G, Hensor EMA, et al
    Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study.
    Arthritis Res Ther. 2018;20:266.
    PubMed     Abstract available


    November 2018
  215. LOFGREN M, Opava CH, Demmelmaier I, Friden C, et al
    Long-term, health-enhancing physical activity is associated with reduction of pain but not pain sensitivity or improved exercise-induced hypoalgesia in persons with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:262.
    PubMed     Abstract available


  216. TEN BRINCK RM, van Steenbergen HW, van der Helm-van Mil AHM
    Sequence of joint tissue inflammation during rheumatoid arthritis development.
    Arthritis Res Ther. 2018;20:260.
    PubMed     Abstract available


  217. ROODENRIJS NMT, de Hair MJH, Wheater G, Elshahaly M, et al
    The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
    Arthritis Res Ther. 2018;20:256.
    PubMed     Abstract available


    October 2018
  218. LEE YA, Hahm DH, Kim JY, Sur B, et al
    Potential therapeutic antibodies targeting specific adiponectin isoforms in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:245.
    PubMed     Abstract available


  219. CONTRERAS-YANEZ I, Ruiz-Medrano E, Hernandez LDCR, Pascual-Ramos V, et al
    Psychometric validation of an empowerment scale for Spanish-speaking patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:244.
    PubMed     Abstract available


  220. GUGGINO G, Orlando V, Saieva L, Ruscitti P, et al
    Downregulation of miRNA17-92 cluster marks Vgamma9Vdelta2 T cells from patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:236.
    PubMed     Abstract available


  221. RITSCHL V, Lackner A, Bostrom C, Mosor E, et al
    I do not want to suppress the natural process of inflammation: new insights on factors associated with non-adherence in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:234.
    PubMed     Abstract available


  222. TEITSMA XM, Yang W, Jacobs JWG, Petho-Schramm A, et al
    Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
    Arthritis Res Ther. 2018;20:230.
    PubMed     Abstract available


  223. DAVIGNON JL, Rauwel B, Degboe Y, Constantin A, et al
    Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.
    Arthritis Res Ther. 2018;20:229.
    PubMed     Abstract available


  224. WANG S, Wang L, Wu C, Sun S, et al
    E2F2 directly regulates the STAT1 and PI3K/AKT/NF-kappaB pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts.
    Arthritis Res Ther. 2018;20:225.
    PubMed     Abstract available


  225. TERSLEV L, Ostergaard M, Sexton J, Hammer HB, et al
    Is synovial hypertrophy without Doppler activity sensitive to change? Post-hoc analysis from a rheumatoid arthritis ultrasound study.
    Arthritis Res Ther. 2018;20:224.
    PubMed     Abstract available


  226. ZHANG LM, Zhou JJ, Luo CL
    CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-kappaB activation.
    Arthritis Res Ther. 2018;20:219.
    PubMed     Abstract available


    September 2018
  227. SZEREMETA A, Jura-Poltorak A, Kozma EM, Glowacki A, et al
    Effects of a 15-month anti-TNF-alpha treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:211.
    PubMed     Abstract available


    August 2018
  228. THAI TN, Dawwas GK
    Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study".
    Arthritis Res Ther. 2018;20:198.
    PubMed    


  229. NIU Q, Huang ZC, Wu XJ, Jin YX, et al
    Enhanced IL-6/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper/T follicular regulatory cells in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:200.
    PubMed     Abstract available


  230. IWAMOTO N, Fukui S, Takatani A, Shimizu T, et al
    Osteogenic differentiation of fibroblast-like synovial cells in rheumatoid arthritis is induced by microRNA-218 through a ROBO/Slit pathway.
    Arthritis Res Ther. 2018;20:189.
    PubMed     Abstract available


  231. FLEISCHMANN RM, Alten R, Pileckyte M, Lobello K, et al
    A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira(R)) in the treatment of active rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:178.
    PubMed     Abstract available


  232. JOHANSSON K, Askling J, Alfredsson L, Di Giuseppe D, et al
    Mediterranean diet and risk of rheumatoid arthritis: a population-based case-control study.
    Arthritis Res Ther. 2018;20:175.
    PubMed     Abstract available


  233. HASHIMOTO M, Furu M, Yamamoto W, Fujimura T, et al
    Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Arthritis Res Ther. 2018;20:165.
    PubMed     Abstract available


  234. NARASIMHAN R, Coras R, Rosenthal SB, Sweeney SR, et al
    Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:164.
    PubMed     Abstract available


  235. ISHII S, Isozaki T, Furuya H, Takeuchi H, et al
    ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion.
    Arthritis Res Ther. 2018;20:159.
    PubMed     Abstract available


    July 2018
  236. COHEN SB, Alten R, Kameda H, Hala T, et al
    A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Arthritis Res Ther. 2018;20:155.
    PubMed     Abstract available


  237. ANGIOLILLI C, Kabala PA, Grabiec AM, Rossato M, et al
    Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.
    Arthritis Res Ther. 2018;20:148.
    PubMed     Abstract available


  238. ALDRIDGE J, Pandya JM, Meurs L, Andersson K, et al
    Sex-based differences in association between circulating T cell subsets and disease activity in untreated early rheumatoid arthritis patients.
    Arthritis Res Ther. 2018;20:150.
    PubMed     Abstract available


  239. TANAKA Y, Kameda H, Saito K, Kaneko Y, et al
    Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naive rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
    Arthritis Res Ther. 2018;20:151.
    PubMed     Abstract available


  240. JONSSON MK, Hensvold AH, Hansson M, Aga AB, et al
    The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
    Arthritis Res Ther. 2018;20:146.
    PubMed     Abstract available


  241. SERGEANT JC, Hyrich KL, Anderson J, Kopec-Harding K, et al
    Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).
    Arthritis Res Ther. 2018;20:147.
    PubMed     Abstract available


    June 2018
  242. CHEN YL, Jing J, Mo YQ, Ma JD, et al
    Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:130.
    PubMed     Abstract available


  243. STRAND V, Gossec L, Proudfoot CWJ, Chen CI, et al
    Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:129.
    PubMed     Abstract available


  244. BARTLETT DB, Willis LH, Slentz CA, Hoselton A, et al
    Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study.
    Arthritis Res Ther. 2018;20:127.
    PubMed     Abstract available


  245. QIAN J, Xu L, Sun X, Wang Y, et al
    Correction to: Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:125.
    PubMed     Abstract available


  246. CHANDRASEKHARAN UM, Wang Z, Wu Y, Wilson Tang WH, et al
    Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:123.
    PubMed     Abstract available


  247. RIVIERE E, Sellam J, Pascaud J, Ravaud P, et al
    Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:122.
    PubMed     Abstract available


    May 2018
  248. WEINBLATT ME
    Methotrexate: who would have predicted its importance in rheumatoid arthritis?
    Arthritis Res Ther. 2018;20:103.
    PubMed    


  249. RIFBJERG-MADSEN S, Christensen AW, Boesen M, Christensen R, et al
    The course of pain hypersensitivity according to painDETECT in patients with rheumatoid arthritis initiating treatment: results from the prospective FRAME-cohort study.
    Arthritis Res Ther. 2018;20:105.
    PubMed     Abstract available


  250. BALOGH E, Veale DJ, McGarry T, Orr C, et al
    Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:95.
    PubMed     Abstract available


  251. DRUCE KL, Aikman L, Dilleen M, Burden A, et al
    Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.
    Arthritis Res Ther. 2018;20:96.
    PubMed     Abstract available


  252. BOETERS DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW, et al
    Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example.
    Arthritis Res Ther. 2018;20:94.
    PubMed     Abstract available


  253. BOER AC, Ten Brinck RM, Evers AWM, van der Helm-van Mil AHM, et al
    Does psychological stress in patients with clinically suspect arthralgia associate with subclinical inflammation and progression to inflammatory arthritis?
    Arthritis Res Ther. 2018;20:93.
    PubMed     Abstract available


  254. TEN BRINCK RM, Toes REM, van der Helm-van Mil AHM
    Inflammation functions as a key mediator in the link between ACPA and erosion development: an association study in Clinically Suspect Arthralgia.
    Arthritis Res Ther. 2018;20:89.
    PubMed     Abstract available


  255. RYDELL E, Forslind K, Nilsson JA, Jacobsson LTH, et al
    Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:82.
    PubMed     Abstract available


  256. ENGDAHL C, Bondt A, Harre U, Raufer J, et al
    Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women.
    Arthritis Res Ther. 2018;20:84.
    PubMed     Abstract available


  257. COLE S, Walsh A, Yin X, Wechalekar MD, et al
    Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
    Arthritis Res Ther. 2018;20:85.
    PubMed     Abstract available


  258. KAN HJ, Dyagilev K, Schulam P, Saria S, et al
    Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.
    Arthritis Res Ther. 2018;20:79.
    PubMed     Abstract available


  259. CHEN YL, Lin JZ, Mo YQ, Ma JD, et al
    Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
    Arthritis Res Ther. 2018;20:81.
    PubMed     Abstract available


    April 2018
  260. ZHOU YZ, Zhao LD, Chen H, Zhang Y, et al
    Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.
    Arthritis Res Ther. 2018;20:70.
    PubMed     Abstract available


  261. BURGERS LE, Boeters DM, Reijnierse M, van der Helm-van Mil AHM, et al
    Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study.
    Arthritis Res Ther. 2018;20:68.
    PubMed     Abstract available


  262. KAWAGUCHI H, Matsumoto I, Osada A, Kurata I, et al
    Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:66.
    PubMed     Abstract available


    March 2018
  263. MACHADO MAA, Moura CS, Guerra SF, Curtis JR, et al
    Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Arthritis Res Ther. 2018;20:60.
    PubMed     Abstract available


  264. CAPPELLI LC, Konig MF, Gelber AC, Bingham CO 3rd, et al
    Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:59.
    PubMed     Abstract available


  265. GENOVESE M, Westhovens R, Meuleners L, Van der Aa A, et al
    Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
    Arthritis Res Ther. 2018;20:57.
    PubMed     Abstract available


  266. SUZUKI K, Yoshida K, Ueha T, Kaneshiro K, et al
    Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.
    Arthritis Res Ther. 2018;20:55.
    PubMed     Abstract available


  267. MUELLER SM, Aguayo D, Aeberli D, Vogelin E, et al
    Myocellular characteristics in rheumatoid arthritis and osteoarthritis patients.
    Arthritis Res Ther. 2018;20:51.
    PubMed    


  268. BERGSTROM B, Carlsten H, Ekwall AH
    Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1beta on rheumatoid arthritis fibroblast-like synoviocytes.
    Arthritis Res Ther. 2018;20:49.
    PubMed     Abstract available


  269. LOFGREN M, Opava CH, Demmelmaier I, Friden C, et al
    Pain sensitivity at rest and during muscle contraction in persons with rheumatoid arthritis: a substudy within the Physical Activity in Rheumatoid Arthritis 2010 study.
    Arthritis Res Ther. 2018;20:48.
    PubMed     Abstract available


  270. SCHWEDLER C, Haupl T, Kalus U, Blanchard V, et al
    Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.
    Arthritis Res Ther. 2018;20:44.
    PubMed     Abstract available


  271. WANG K, Zhang D, Liu Y, Wang X, et al
    Traditional Chinese medicine formula Bi-Qi capsule alleviates rheumatoid arthritis-induced inflammation, synovial hyperplasia, and cartilage destruction in rats.
    Arthritis Res Ther. 2018;20:43.
    PubMed     Abstract available


  272. TAKEUCHI T, Yamanaka H, Harigai M, Tamamura R, et al
    Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
    Arthritis Res Ther. 2018;20:42.
    PubMed     Abstract available


    February 2018
  273. HAHNLEIN JS, Nadafi R, de Jong T, Ramwadhdoebe TH, et al
    Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:35.
    PubMed     Abstract available


  274. DE MOEL EC, Derksen VFAM, Stoeken G, Trouw LA, et al
    Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.
    Arthritis Res Ther. 2018;20:33.
    PubMed     Abstract available


  275. QIAN J, Xu L, Sun X, Wang Y, et al
    Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:26.
    PubMed     Abstract available


    January 2018
  276. CHOWDHURY K, Kumar U, Das S, Chaudhuri J, et al
    Synovial IL-9 facilitates neutrophil survival, function and differentiation of Th17 cells in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:18.
    PubMed     Abstract available


  277. TEN CATE DF, Jacobs JWG, Swen WAA, Hazes JMW, et al
    Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?
    Arthritis Res Ther. 2018;20:15.
    PubMed     Abstract available


  278. CHENG TT, Yu SF, Su FM, Chen YC, et al
    Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX(R): a registry study of RA with osteoporosis/fracture.
    Arthritis Res Ther. 2018;20:16.
    PubMed     Abstract available


  279. SMOLEN JS, Szumski A, Koenig AS, Jones TV, et al
    Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Arthritis Res Ther. 2018;20:8.
    PubMed     Abstract available


  280. HARROLD LR, Litman HJ, Saunders KC, Dandreo KJ, et al
    One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
    Arthritis Res Ther. 2018;20:2.
    PubMed     Abstract available


  281. ALTEN R, Burkhardt H, Feist E, Kruger K, et al
    Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Arthritis Res Ther. 2018;20:1.
    PubMed     Abstract available


    December 2017
  282. OUBOUSSAD L, Hunt L, Hensor EMA, Nam JL, et al
    Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:288.
    PubMed     Abstract available


  283. CHO SK, Lee J, Han M, Bae SC, et al
    The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Arthritis Res Ther. 2017;19:277.
    PubMed     Abstract available


  284. CURTIS JR, Winthrop K, O'Brien C, Ndlovu MN, et al
    Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
    Arthritis Res Ther. 2017;19:276.
    PubMed     Abstract available


  285. KUCA-WARNAWIN E, Kurowska W, Prochorec-Sobieszek M, Radzikowska A, et al
    Rheumatoid arthritis bone marrow environment supports Th17 response.
    Arthritis Res Ther. 2017;19:274.
    PubMed     Abstract available


  286. SATO H, Muraoka S, Kusunoki N, Masuoka S, et al
    Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:263.
    PubMed     Abstract available


  287. LAI NS, Yu HC, Tung CH, Huang KY, et al
    The role of aberrant expression of T cell miRNAs affected by TNF-alpha in the immunopathogenesis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:261.
    PubMed     Abstract available


    November 2017
  288. BERGSTRA SA, Allaart CF, van den Berg R, Chopra A, et al
    Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:258.
    PubMed     Abstract available


  289. YANG X, Lin K, Ni S, Wang J, et al
    Serum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:257.
    PubMed     Abstract available


  290. JIN S, Li M, Fang Y, Li Q, et al
    Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:251.
    PubMed     Abstract available


  291. BLACK RJ, Lester S, Buchbinder R, Barrett C, et al
    Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry.
    Arthritis Res Ther. 2017;19:253.
    PubMed     Abstract available


  292. ZHOU L, Wang G, Liu X, Song J, et al
    Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:250.
    PubMed     Abstract available


  293. ANAPARTI V, Smolik I, Meng X, Spicer V, et al
    Whole blood microRNA expression pattern differentiates patients with rheumatoid arthritis, their seropositive first-degree relatives, and healthy unrelated control subjects.
    Arthritis Res Ther. 2017;19:249.
    PubMed     Abstract available


    October 2017
  294. JOO YB, Kim Y, Park Y, Kim K, et al
    Biological function integrated prediction of severe radiographic progression in rheumatoid arthritis: a nested case control study.
    Arthritis Res Ther. 2017;19:244.
    PubMed     Abstract available


  295. ROMAO VC, Vital EM, Fonseca JE, Buch MH, et al
    Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
    Arthritis Res Ther. 2017;19:239.
    PubMed     Abstract available


  296. MCQUEEN FM, Chapman P, Pollock T, D'Souza D, et al
    Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:241.
    PubMed     Abstract available


  297. MANDL T, Marsal J, Olsson P, Ohlsson B, et al
    Severe intestinal dysbiosis is prevalent in primary Sjogren's syndrome and is associated with systemic disease activity.
    Arthritis Res Ther. 2017;19:237.
    PubMed     Abstract available


  298. SAITO S, Suzuki K, Yoshimoto K, Kaneko Y, et al
    A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:231.
    PubMed     Abstract available


  299. TEJERA-SEGURA B, Lopez-Mejias R, Dominguez-Luis MJ, de Vera-Gonzalez AM, et al
    Incretins in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:229.
    PubMed     Abstract available


  300. SHIMIZU T, Choi HJ, Heilmeier U, Tanaka M, et al
    Assessment of 3-month changes in bone microstructure under anti-TNFalpha therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
    Arthritis Res Ther. 2017;19:222.
    PubMed     Abstract available


  301. HAMMER HB, Kvien TK, Terslev L
    Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study.
    Arthritis Res Ther. 2017;19:221.
    PubMed     Abstract available


    September 2017
  302. BERGSTRA SA, Olivas O, Akdemir G, Riyazi N, et al
    Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.
    Arthritis Res Ther. 2017;19:220.
    PubMed     Abstract available


  303. SHERINA N, Hreggvidsdottir HS, Bengtsson C, Hansson M, et al
    Low levels of antibodies against common viruses associate with anti-citrullinated protein antibody-positive rheumatoid arthritis; implications for disease aetiology.
    Arthritis Res Ther. 2017;19:219.
    PubMed     Abstract available


  304. CURTIS JR, Herrem C, Ndlovu 'N, O'Brien C, et al
    A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
    Arthritis Res Ther. 2017;19:215.
    PubMed     Abstract available


  305. OLAH C, Kardos Z, Sepsi M, Sas A, et al
    Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:213.
    PubMed     Abstract available


  306. CHALLA DN, Kvrgic Z, Cheville AL, Crowson CS, et al
    Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation.
    Arthritis Res Ther. 2017;19:212.
    PubMed     Abstract available


  307. SCHIFF M, Takeuchi T, Fleischmann R, Gaich CL, et al
    Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Arthritis Res Ther. 2017;19:208.
    PubMed     Abstract available


  308. KABALA PA, Angiolilli C, Yeremenko N, Grabiec AM, et al
    Endoplasmic reticulum stress cooperates with Toll-like receptor ligation in driving activation of rheumatoid arthritis fibroblast-like synoviocytes.
    Arthritis Res Ther. 2017;19:207.
    PubMed     Abstract available


  309. TAKEUCHI T, Miyasaka N, Inui T, Yano T, et al
    High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the R
    Arthritis Res Ther. 2017;19:194.
    PubMed     Abstract available


  310. ZIEGELASCH M, Forslind K, Skogh T, Riklund K, et al
    Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year.
    Arthritis Res Ther. 2017;19:195.
    PubMed     Abstract available


    August 2017
  311. SHAH NR, Noll BD, Stevens CB, Brennan MT, et al
    Biosemantics guided gene expression profiling of Sjogren's syndrome: a comparative analysis with systemic lupus erythematosus and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:192.
    PubMed     Abstract available


  312. VAN DELFT MAM, Verheul MK, Burgers LE, Derksen VFAM, et al
    The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients.
    Arthritis Res Ther. 2017;19:190.
    PubMed     Abstract available


  313. NAKAGAWA J, Koyama Y, Kawakami A, Ueki Y, et al
    A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Arthritis Res Ther. 2017;19:185.
    PubMed     Abstract available


  314. LUNDSTROM SL, Hensvold AH, Rutishauser D, Klareskog L, et al
    IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:182.
    PubMed     Abstract available


    July 2017
  315. JAMSHIDI A, Gharibdoost F, Vojdanian M, Soroosh SG, et al
    A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA(R)) to the reference product (Humira(R)) in patients with active rheumat
    Arthritis Res Ther. 2017;19:168.
    PubMed     Abstract available


  316. TEITSMA XM, Jacobs JWG, Mokry M, Borm MEA, et al
    Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.
    Arthritis Res Ther. 2017;19:170.
    PubMed     Abstract available


  317. MACLAUCHLAN S, Zuriaga MA, Fuster JJ, Cuda CM, et al
    Genetic deficiency of Wnt5a diminishes disease severity in a murine model of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:166.
    PubMed     Abstract available


  318. BONDT A, Nicolardi S, Jansen BC, Kuijper TM, et al
    IgA N- and O-glycosylation profiling reveals no association with the pregnancy-related improvement in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:160.
    PubMed     Abstract available


  319. JIN Y, Desai RJ, Liu J, Choi NK, et al
    Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:159.
    PubMed     Abstract available


  320. SCHOELS M, Alasti F, Smolen JS, Aletaha D, et al
    Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Arthritis Res Ther. 2017;19:155.
    PubMed     Abstract available


  321. CASTANEDA S, Llorente I, Garcia-Vicuna R, Gonzalez-Alvaro I, et al
    Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article "Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untr
    Arthritis Res Ther. 2017;19:152.
    PubMed    


  322. OH BR, Suh DH, Bae D, Ha N, et al
    Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
    Arthritis Res Ther. 2017;19:154.
    PubMed     Abstract available


    June 2017
  323. KOKKONEN H, Stenlund H, Rantapaa-Dahlqvist S
    Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case-control study.
    Arthritis Res Ther. 2017;19:148.
    PubMed     Abstract available


  324. CABRERA-VILLALBA S, Gomara MJ, Canete JD, Ramirez J, et al
    Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:141.
    PubMed     Abstract available


  325. SOLOMON DH, Shadick NA, Weinblatt ME, Zak A, et al
    Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.
    Arthritis Res Ther. 2017;19:130.
    PubMed     Abstract available


  326. WANG J, Wen Y, Zhou M, Shi X, et al
    Ectopic germinal center and megalin defect in primary Sjogren syndrome with renal Fanconi syndrome.
    Arthritis Res Ther. 2017;19:120.
    PubMed     Abstract available


    May 2017
  327. TEJERA-SEGURA B, Macia-Diaz M, Machado JD, de Vera-Gonzalez A, et al
    HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.
    Arthritis Res Ther. 2017;19:113.
    PubMed     Abstract available


  328. BOETERS DM, Mangnus L, Ajeganova S, Lindqvist E, et al
    The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.
    Arthritis Res Ther. 2017;19:115.
    PubMed     Abstract available


  329. YOO J, Lee SK, Lim M, Sheen D, et al
    Exosomal amyloid A and lymphatic vessel endothelial hyaluronic acid receptor-1 proteins are associated with disease activity in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:119.
    PubMed     Abstract available


  330. BUSTAMANTE MF, Garcia-Carbonell R, Whisenant KD, Guma M, et al
    Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:110.
    PubMed     Abstract available


  331. SHODA H, Nagafuchi Y, Tsuchida Y, Sakurai K, et al
    Increased serum concentrations of IL-1 beta, IL-21 and Th17 cells in overweight patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:111.
    PubMed     Abstract available


  332. CHANDRUPATLA DMSH, Jansen G, Vos R, Verlaan M, et al
    In-vivo monitoring of anti-folate therapy in arthritic rats using [(18)F]fluoro-PEG-folate and positron emission tomography.
    Arthritis Res Ther. 2017;19:114.
    PubMed     Abstract available


  333. ALDRICH MB, Velasquez FC, Kwon S, Azhdarinia A, et al
    Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis.
    Arthritis Res Ther. 2017;19:116.
    PubMed     Abstract available


  334. KAWASHIRI SY, Fujikawa K, Nishino A, Okada A, et al
    Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are
    Arthritis Res Ther. 2017;19:108.
    PubMed     Abstract available


  335. GOIN DE, Smed MK, Pachter L, Purdom E, et al
    Pregnancy-induced gene expression changes in vivo among women with rheumatoid arthritis: a pilot study.
    Arthritis Res Ther. 2017;19:104.
    PubMed     Abstract available


  336. DERAMBURE C, Dzangue-Tchoupou G, Berard C, Vergne N, et al
    Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:109.
    PubMed     Abstract available


  337. PENATTI A, Facciotti F, De Matteis R, Larghi P, et al
    Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:103.
    PubMed     Abstract available


  338. THIEL J, Rizzi M, Engesser M, Dufner AK, et al
    B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Arthritis Res Ther. 2017;19:101.
    PubMed     Abstract available


  339. NAKACHI S, Sumitomo S, Tsuchida Y, Tsuchiya H, et al
    Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:97.
    PubMed     Abstract available


  340. GRABNER M, Boytsov NN, Huang Q, Zhang X, et al
    Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
    Arthritis Res Ther. 2017;19:92.
    PubMed     Abstract available


  341. STANDISH KA, Huang CC, Curran ME, Schork NJ, et al
    Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies.
    Arthritis Res Ther. 2017;19:90.
    PubMed     Abstract available


  342. SAUER BC, Teng CC, Accortt NA, Burningham Z, et al
    Models solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activity.
    Arthritis Res Ther. 2017;19:86.
    PubMed     Abstract available


  343. RYKOVA E, Sizikov A, Roggenbuck D, Antonenko O, et al
    Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers.
    Arthritis Res Ther. 2017;19:85.
    PubMed     Abstract available


    April 2017
  344. REED GW, Collier DH, Koenig AS, Saunders KC, et al
    Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:81.
    PubMed     Abstract available


  345. ISSA SF, Duer A, Ostergaard M, Horslev-Petersen K, et al
    Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets.
    Arthritis Res Ther. 2017;19:80.
    PubMed     Abstract available


  346. KUIJPER TM, Folmer R, Stolk EA, Hazes JMW, et al
    Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.
    Arthritis Res Ther. 2017;19:78.
    PubMed     Abstract available


  347. ANDRES CEREZO L, Sumova B, Prajzlerova K, Veigl D, et al
    Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:79.
    PubMed     Abstract available


  348. KUULIALA K, Kuuliala A, Koivuniemi R, Kautiainen H, et al
    Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:75.
    PubMed     Abstract available


  349. TAKAHASHI S, Saegusa J, Sendo S, Okano T, et al
    Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:76.
    PubMed     Abstract available


  350. KILTZ U, von Zabern C, Baraliakos X, Heldmann F, et al
    Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study.
    Arthritis Res Ther. 2017;19:73.
    PubMed     Abstract available


    March 2017
  351. MENG W, Zhu Z, Jiang X, Too CL, et al
    DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:71.
    PubMed     Abstract available


  352. ALBRECHT K, Zink A
    Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.
    Arthritis Res Ther. 2017;19:68.
    PubMed     Abstract available


  353. JIANG J, Liu C, Liu M, Shen Y, et al
    OX40 signaling is involved in the autoactivation of CD4+CD28- T cells and contributes to the pathogenesis of autoimmune arthritis.
    Arthritis Res Ther. 2017;19:67.
    PubMed     Abstract available


  354. VAN DEN BRANDT S, Zbinden A, Baeten D, Villiger PM, et al
    Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
    Arthritis Res Ther. 2017;19:64.
    PubMed     Abstract available


  355. PERES RS, Santos GB, Cecilio NT, Jabor VA, et al
    Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis.
    Arthritis Res Ther. 2017;19:47.
    PubMed     Abstract available


  356. CURTIS JR, Chen L, Higginbotham P, Nowell WB, et al
    Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising.
    Arthritis Res Ther. 2017;19:48.
    PubMed     Abstract available


  357. OLSSON P, Turesson C, Mandl T, Jacobsson L, et al
    Cigarette smoking and the risk of primary Sjogren's syndrome: a nested case control study.
    Arthritis Res Ther. 2017;19:50.
    PubMed     Abstract available


    February 2017
  358. KLEYER A, Beyer L, Simon C, Stemmler F, et al
    Development of three-dimensional prints of arthritic joints for supporting patients' awareness to structural damage.
    Arthritis Res Ther. 2017;19:34.
    PubMed     Abstract available


  359. CROWLEY T, O'Neil JD, Adams H, Thomas AM, et al
    Priming in response to pro-inflammatory cytokines is a feature of adult synovial but not dermal fibroblasts.
    Arthritis Res Ther. 2017;19:35.
    PubMed     Abstract available


    January 2017
  360. AQRAWI LA, Galtung HK, Vestad B, Ovstebo R, et al
    Identification of potential saliva and tear biomarkers in primary Sjogren's syndrome, utilising the extraction of extracellular vesicles and proteomics analysis.
    Arthritis Res Ther. 2017;19:14.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: